Introduction: Patients with consistent suspicion for prostate cancer (PCa) and multiple negative prebiopsies prior to multiparametric magnetic resonance imaging (mpMRI) are still frequently evaluated for an image-guided biopsy and are reported with heterogeneous detection rates. The inclusion of a systematic biopsy (SB) is also still recommended with predominant sampling within the posterior/peripheral zone of the prostate. The aim of this study was (I) to evaluate PCa detection rates using a modified 10 core SB template including anterior biopsies in combination with mpMRI/ultrasound fusion-guided targeted biopsy (TB) in patients with 3 or more negative prebiopsies and (II) to compare mpMRI index lesion localization with histologically confirmed locali-zation from associated prostatectomy samples. Methods: Overall 1,337 consecutive patients underwent sensor-based registration TB of the prostate and a subsequent 10-core SB between January 2012 and December 2015 at our institution. For this study, 101 patients with ≥3 negative prebiopsies and prostate imaging – reporting data system lesions ≥3 were pooled prospectively and underwent TB and a modified SB including 2 ventral (anterior) biopsies. Detection rates were estimated for the modified SB, TB, and its combination. A subgroup analysis of 35 patients undergoing prostatectomy was performed by a head-to-head comparison of mpMRI index lesion and histologically confirmed PCa index lesion localization. Results: The overall detection rate for PCa was 54.5%. The combination of TB and SB detected 14 (25.4%) more cases missed by TB alone (p < 0.001) and 7 (12.7%) more cases missed by SB alone (p = 0.016), respectively. A postoperative Gleason upgrade was seen in 12/35 (34.3%) cases within the TB group and in 14/35 (40.0%) in the SB group, respectively. The subgroup analysis showed a predominant location of PCa index lesions anteriorly at the level of the midgland. The MRI detection rate of the anteriorly located index lesions was 70.4% (15/21 cases) with a clinically significant Gleason score (≥3 + 4 = 7a [International Society of Urological Pathology grade 2]) in 80.9%. Interestingly a modified SB template detected 90.5% (19/21) of the anteriorly located index lesions. Conclusion: Our data suggest that in patients with multiple prebiopsies PCa seems to be predominantly located anteriorly. We suggest the general integration of anterior biopsies despite TB in repeat biopsy patients.

1.
Pokorny
MR
,
de Rooij
M
,
Duncan
E
,
Schröder
FH
,
Parkinson
R
,
Barentsz
JO
, et al.
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies
.
Eur Urol
.
2014
Jul
;
66
(
1
):
22
9
.
[PubMed]
0302-2838
2.
Siddiqui
MM
,
Rais-Bahrami
S
,
Turkbey
B
,
George
AK
,
Rothwax
J
,
Shakir
N
, et al.
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer
.
JAMA
.
2015
Jan
;
313
(
4
):
390
7
.
[PubMed]
0098-7484
3.
Barentsz
JO
,
Richenberg
J
,
Clements
R
,
Choyke
P
,
Verma
S
,
Villeirs
G
, et al.;
European Society of Urogenital Radiology
.
ESUR prostate MR guidelines 2012
.
Eur Radiol
.
2012
Apr
;
22
(
4
):
746
57
.
[PubMed]
0938-7994
4.
Cash
H
,
Maxeiner
A
,
Stephan
C
,
Fischer
T
,
Durmus
T
,
Holzmann
J
, et al.
The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy
.
World J Urol
.
2016
Apr
;
34
(
4
):
525
32
.
[PubMed]
0724-4983
5.
Ahmed
HU
.
The index lesion and the origin of prostate cancer
.
N Engl J Med
.
2009
Oct
;
361
(
17
):
1704
6
.
[PubMed]
0028-4793
6.
Filson
CP
,
Natarajan
S
,
Margolis
DJ
,
Huang
J
,
Lieu
P
,
Dorey
FJ
, et al.
Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies
.
Cancer
.
2016
Mar
;
122
(
6
):
884
92
.
[PubMed]
0008-543X
7.
Turkbey
B
,
Pinto
PA
,
Mani
H
,
Bernardo
M
,
Pang
Y
,
McKinney
YL
, et al.
Prostate cancer: value of multiparametric MR imaging at 3 T for detection—histopathologic correlation
.
Radiology
.
2010
Apr
;
255
(
1
):
89
99
.
[PubMed]
0033-8419
8.
Radtke
JP
,
Schwab
C
,
Wolf
MB
,
Freitag
MT
,
Alt
CD
,
Kesch
C
, et al.
Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen
.
Eur Urol
.
2016
Nov
;
70
(
5
):
846
53
.
[PubMed]
0302-2838
9.
Hanna
N
,
Wszolek
MF
,
Mojtahed
A
,
Nicaise
E
,
Wu
B
,
Gelpi-Hammerschmidt
FJ
, et al.
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves But Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer. J Urol.
2019
:101097JU0000000000000359.
10.
Le
JD
,
Tan
N
,
Shkolyar
E
,
Lu
DY
,
Kwan
L
,
Marks
LS
, et al.
Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology
.
Eur Urol
.
2015
Mar
;
67
(
3
):
569
76
.
[PubMed]
0302-2838
11.
Kasivisvanathan
V
,
Rannikko
AS
,
Borghi
M
,
Panebianco
V
,
Mynderse
LA
,
Vaarala
MH
, et al.;
PRECISION Study Group Collaborators
.
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
.
N Engl J Med
.
2018
May
;
378
(
19
):
1767
77
.
[PubMed]
0028-4793
12.
Ahmed
HU
,
El-Shater Bosaily
A
,
Brown
LC
,
Gabe
R
,
Kaplan
R
,
Parmar
MK
, et al.;
PROMIS study group
.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
.
Lancet
.
2017
Feb
;
389
(
10071
):
815
22
.
[PubMed]
0140-6736
13.
van der Leest
M
,
Cornel
E
,
Israel
B
,
Hendriks
R
,
Padhani
AR
,
Hoogenboom
M
, et al.
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study
.
Eur Urol
.
2018
.
[PubMed]
0302-2838
14.
Mottet
N
,
Bellmunt
J
,
Bolla
M
,
Briers
E
,
Cumberbatch
MG
,
De Santis
M
, et al.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
.
Eur Urol
.
2017
Apr
;
71
(
4
):
618
29
.
[PubMed]
0302-2838
15.
Djavan
B
,
Ravery
V
,
Zlotta
A
,
Dobronski
P
,
Dobrovits
M
,
Fakhari
M
, et al.
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
J Urol
.
2001
Nov
;
166
(
5
):
1679
83
.
[PubMed]
0022-5347
16.
Ploussard
G
,
Nicolaiew
N
,
Marchand
C
,
Terry
S
,
Allory
Y
,
Vacherot
F
, et al.
Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial
.
BJU Int
.
2013
May
;
111
(
6
):
988
96
.
[PubMed]
1464-4096
17.
Haffner
J
,
Potiron
E
,
Bouyé
S
,
Puech
P
,
Leroy
X
,
Lemaitre
L
, et al.
Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology
.
Prostate
.
2009
Feb
;
69
(
3
):
276
82
.
[PubMed]
0270-4137
18.
Mygatt
J
,
Sesterhenn
I
,
Rosner
I
,
Chen
Y
,
Cullen
J
,
Morris-Gore
T
, et al.
Anterior tumors of the prostate: clinicopathological features and outcomes
.
Prostate Cancer Prostatic Dis
.
2014
Mar
;
17
(
1
):
75
80
.
[PubMed]
1365-7852
19.
Boesen
L
,
Nørgaard
N
,
Løgager
V
,
Balslev
I
,
Thomsen
HS
.
Where Do Transrectal Ultrasound- and Magnetic Resonance Imaging-guided Biopsies Miss Significant Prostate Cancer?
Urology
.
2017
Dec
;
110
:
154
60
.
[PubMed]
0090-4295
20.
Krughoff
K
,
Eid
K
,
Phillips
J
,
Stoimenova
D
,
Smith
D
,
O’Donnell
C
, et al.
The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach
.
Adv Urol
.
2013
;
2013
:
249080
.
[PubMed]
1687-6369
21.
Schouten
MG
,
Hoeks
CM
,
Bomers
JG
,
Hulsbergen-van de Kaa
CA
,
Witjes
JA
,
Thompson
LC
, et al.
Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy
.
AJR Am J Roentgenol
.
2015
Jul
;
205
(
1
):
57
63
.
[PubMed]
0361-803X
22.
Wegelin
O
,
van Melick
HH
,
Hooft
L
,
Bosch
JL
,
Reitsma
HB
,
Barentsz
JO
, et al.
Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?
Eur Urol
.
2017
Apr
;
71
(
4
):
517
31
.
[PubMed]
0302-2838
23.
Moussa
AS
,
Meshref
A
,
Schoenfield
L
,
Masoud
A
,
Abdel-Rahman
S
,
Li
J
, et al.
Importance of additional “extreme” anterior apical needle biopsies in the initial detection of prostate cancer
.
Urology
.
2010
May
;
75
(
5
):
1034
9
.
[PubMed]
0090-4295
24.
O’Neil
LM
,
Walsh
S
,
Cohen
RJ
,
Lee
S
.
Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence
.
BJU Int
.
2015
Oct
;
116
Suppl 3
:
42
8
.
[PubMed]
1464-4096
25.
Dickinson
L
,
Ahmed
HU
,
Allen
C
,
Barentsz
JO
,
Carey
B
,
Futterer
JJ
, et al.
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting
.
Eur Urol
.
2011
Apr
;
59
(
4
):
477
94
.
[PubMed]
0302-2838
26.
Borkowetz
A
,
Hadaschik
B
,
Platzek
I
,
Toma
M
,
Torsev
G
,
Renner
T
, et al.
Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients
.
BJU Int
.
2018
Jan
;
121
(
1
):
53
60
.
[PubMed]
1464-4096
27.
Cash
H
,
Günzel
K
,
Maxeiner
A
,
Stephan
C
,
Fischer
T
,
Durmus
T
, et al.
Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure
.
BJU Int
.
2016
Jul
;
118
(
1
):
35
43
.
[PubMed]
1464-4096
28.
Westhoff
N
,
Baeßler
B
,
von Hardenberg
J
,
Hetjens
S
,
Porubsky
S
,
Siegel
F
, et al.
Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications
.
Urol Oncol
.
2019
Oct
;
37
(
10
):
678
87
.
[PubMed]
1078-1439
29.
Abraham
NE
,
Mendhiratta
N
,
Taneja
SS
.
Patterns of repeat prostate biopsy in contemporary clinical practice
.
J Urol
.
2015
Apr
;
193
(
4
):
1178
84
.
[PubMed]
0022-5347
30.
Leyh-Bannurah
SR
,
Kachanov
M
,
Beyersdorff
D
,
Preisser
F
,
Tilki
D
,
Fisch
M
, et al.
Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies
.
J Urol
.
2018
Nov
;
200
(
5
):
1035
40
.
[PubMed]
0022-5347
31.
Schouten
MG
,
van der Leest
M
,
Pokorny
M
,
Hoogenboom
M
,
Barentsz
JO
,
Thompson
LC
, et al.
Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Eur Urol
.
2017
Jun
;
71
(
6
):
896
903
.
[PubMed]
0302-2838
32.
Pietzak
EJ
,
Resnick
MJ
,
Mucksavage
P
,
Van Arsdalen
K
,
Wein
AJ
,
Malkowicz
SB
, et al.
Multiple repeat prostate biopsies and the detection of clinically insignificant cancer in men with large prostates
.
Urology
.
2014
Aug
;
84
(
2
):
380
5
.
[PubMed]
0090-4295
33.
Bittner
N
,
Merrick
GS
,
Butler
WM
,
Bennett
A
,
Galbreath
RW
.
Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy
.
J Urol
.
2013
Aug
;
190
(
2
):
509
14
.
[PubMed]
0022-5347
34.
Gershman
B
,
Zietman
AL
,
Feldman
AS
,
McDougal
WS
.
Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies
.
Urol Oncol
.
2013
Oct
;
31
(
7
):
1093
7
.
[PubMed]
1078-1439
35.
Radtke
JP
,
Boxler
S
,
Kuru
TH
,
Wolf
MB
,
Alt
CD
,
Popeneciu
IV
, et al.
Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance
.
Prostate Cancer Prostatic Dis
.
2015
Sep
;
18
(
3
):
288
96
.
[PubMed]
1365-7852
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.